The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates
Open accessAbstract
Containment of highly lethal Ebola virus outbreaks poses a serious public health challenge. Although an experimental vaccine has successfully protected non-human primates against disease, more than six months was required to complete the immunizations, making it impractical to limit an acute epidemic. Here, we report the development of accelerated vaccination against Ebola virus in non-human primates. The antibody response to immunization with an adenoviral (ADV) vector encoding the Ebola glycoprotein (GP) was induced more rapidly than with DNA priming and ADV boosting, but it was of lower magnitude. To determine whether this earlier immune response could nonetheless protect against disease, cynomolgus macaques were challenged with Ebola virus after vaccination with ADV–GP and nucleoprotein (NP) vectors. Protection was highly effective and correlated with the generation of Ebola-specific CD8+ T-cell and antibody responses. Even when animals were immunized once with ADV–GP/NP and challenged 28 days later, they remained resistant to challenge with either low or high doses of virus. This accelerated vaccine provides an intervention that may help to limit the epidemic spread of Ebola, and is applicable to other viruses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A System for Stable Expression of Short Interfering RNAs in Mammalian Cells
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,291
Brewer, G. J., Torricelli, J. R., Evege, E. K., & Price, P. J. (1993) · Journal of Neuroscience Research · doi:10.1002/jnr.490350513 · Cited by 2,325
Neuroligin Expressed in Nonneuronal Cells Triggers Presynaptic Development in Contacting Axons
Scheiffele, P., Fan, J., Choih, J., Fetter, R., & Serafini, T. (2000) · Cell · doi:10.1016/s0092-8674(00)80877-6 · Cited by 1,218
EphB Receptors Interact with NMDA Receptors and Regulate Excitatory Synapse Formation
Dalva, M. B., Takasu, M. A., Lin, M. Z., Shamah, S. M., Hu, L., Gale, N. W., & Greenberg, M. E. (2000) · Cell · doi:10.1016/s0092-8674(00)00197-5 · Cited by 716
Regulation of Dendritic Spine Morphology and Synaptic Function by Shank and Homer
Sala, C., Piëch, V., Wilson, N. R., Passafaro, M., Liu, G., & Sheng, M. (2001) · Neuron · doi:10.1016/s0896-6273(01)00339-7 · Cited by 716
Catastrophic ape decline in western equatorial Africa
Walsh, P. D., Abernethy, K. A., Bermejo, M., Beyers, R., De Wachter, P., Akou, M. E., Huijbregts, B., Mambounga, D. I., Toham, A. K., Kilbourn, A. M., et al. (2003) · Nature · doi:10.1038/nature01566 · Cited by 681
Structure of a glutamate-receptor ligand-binding core in complex with kainate
Armstrong, N., Sun, Y., Chen, G.-Q., & Gouaux, E. (1998) · Nature · doi:10.1038/27692 · Cited by 672
Development of a preventive vaccine for Ebola virus infection in primates
Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z.-Y., & Nabel, G. J. (2000) · Nature · doi:10.1038/35046108 · Cited by 663
Self-citationSubunit-specific temporal and spatial patterns of AMPA receptor exocytosis in hippocampal neurons
Passafaro, M., Piëch, V., & Sheng, M. (2001) · Nature Neuroscience · doi:10.1038/nn0901-917 · Cited by 655
Gene Therapy for Vascular Smooth Muscle Cell Proliferation After Arterial Injury
Ohno, T., Gordon, D., San, H., Pompili, V. J., Imperiale, M. J., Nabel, G. J., & Nabel, E. G. (1994) · Science · doi:10.1126/science.8047883 · Cited by 433
Self-citation
Cited by
Feldmann, H., & Geisbert, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)60667-8 · Cited by 1,374
Self-citationLive attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses
Jones, S. M., Feldmann, H., Ströher, U., Geisbert, J. B., Fernando, L., Grolla, A., Klenk, H.-D., Sullivan, N. J., Volchkov, V. E., Fritz, E. A., et al. (2005) · Nature Medicine · doi:10.1038/nm1258 · Cited by 687
Self-citationAdenoviruses as vaccine vectors
Tatsis, N., & Ertl, H. C. J. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.013 · Cited by 669
New Vaccine Technologies to Combat Outbreak Situations
Rauch, S., Jasny, E., Schmidt, K. E., & Petsch, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01963 · Cited by 579
Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy
Plückthun, A. (2015) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134654 · Cited by 575
Chowell, G., Hengartner, N. W., Castillo-Chavez, C., Fenimore, P. W., & Hyman, J. M. (2004) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2004.03.006 · Cited by 571
Abbink, P., Lemckert, A. A. C., Ewald, B. A., Lynch, D. M., Denholtz, M., Smits, S., Holterman, L., Damen, I., Vogels, R., Thorner, A. R., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02696-06 · Cited by 503
Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity
Roberts, D. M., Nanda, A., Havenga, M. J. E., Abbink, P., Lynch, D. M., Ewald, B. A., Liu, J., Thorner, A. R., Swanson, P. E., Gorgone, D. A., et al. (2006) · Nature · doi:10.1038/nature04721 · Cited by 491
Ebola Virus VP24 Binds Karyopherin α1 and Blocks STAT1 Nuclear Accumulation
Reid, S. P., Leung, L. W., Hartman, A. L., Martinez, O., Shaw, M. L., Carbonnelle, C., Volchkov, V. E., Nichol, S. T., & Basler, C. F. (2006) · Journal of Virology · doi:10.1128/jvi.02349-05 · Cited by 463
“At present, no vaccines against EBOV are licensed for use in humans, although experimental vaccines that are effective in nonhuman primates have been described (34, 59, 60).”
BackgroundExotic emerging viral diseases: progress and challenges
Geisbert, T. W., & Jahrling, P. B. (2004) · Nature Medicine · doi:10.1038/nm1142 · Cited by 441
Self-citationUnderstanding the dynamics of Ebola epidemics
LEGRAND, J., GRAIS, R. F., BOELLE, P. Y., VALLERON, A. J., & FLAHAULT, A. (2007) · Epidemiology and Infection · doi:10.1017/s0950268806007217 · Cited by 436
Garbutt, M., Liebscher, R., Wahl-Jensen, V., Jones, S., Möller, P., Wagner, R., Volchkov, V., Klenk, H.-D., Feldmann, H., & Ströher, U. (2004) · Journal of Virology · doi:10.1128/jvi.78.10.5458-5465.2004 · Cited by 381
Sumida, S. M., Truitt, D. M., Lemckert, A. A. C., Vogels, R., Custers, J. H. H. V., Addo, M. M., Lockman, S., Peter, T., Peyerl, F. W., Kishko, M. G., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.11.7179 · Cited by 369
Olinger, G. G., Pettitt, J., Kim, D., Working, C., Bohorov, O., Bratcher, B., Hiatt, E., Hume, S. D., Johnson, A. K., Morton, J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213709109 · Cited by 366
Jump-starting the immune system: prime–boosting comes of age
Woodland, D. L. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.11.009 · Cited by 346
Catanzaro, A. T., Koup, R. A., Roederer, M., Bailer, R. T., Enama, M. E., Moodie, Z., Gu, L., Martin, J. E., Novik, L., Chakrabarti, B. K., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/509258 · Cited by 321
Self-citationPathogenesis of filoviral haemorrhagic fevers
Mahanty, S., & Bray, M. (2004) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(04)01103-x · Cited by 310
Effective Post-Exposure Treatment of Ebola Infection
Feldmann, H., Jones, S. M., Daddario-DiCaprio, K. M., Geisbert, J. B., Ströher, U., Grolla, A., Bray, M., Fritz, E. A., Fernando, L., Feldmann, F., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030002 · Cited by 288
Self-citationChimpanzee Adenovirus Vector Ebola Vaccine
Ledgerwood, J. E., DeZure, A. D., Stanley, D. A., Coates, E. E., Novik, L., Enama, M. E., Berkowitz, N. M., Hu, Z., Joshi, G., Ploquin, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1410863 · Cited by 285
Self-citationDevelopment of a New Vaccine for the Prevention of Lassa Fever
Geisbert, T. W., Jones, S., Fritz, E. A., Shurtleff, A. C., Geisbert, J. B., Liebscher, R., Grolla, A., Ströher, U., Fernando, L., Daddario, K. M., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020183 · Cited by 279
Self-citationGeisbert, T. W., Geisbert, J. B., Leung, A., Daddario-DiCaprio, K. M., Hensley, L. E., Grolla, A., & Feldmann, H. (2009) · Journal of Virology · doi:10.1128/jvi.00561-09 · Cited by 275
Self-citationUS Biomedical Research: Basic, Translational, and Clinical Sciences
Zerhouni, E. A. (2005) · JAMA · doi:10.1001/jama.294.11.1352 · Cited by 256
Adenoviral vector-based strategies against infectious disease and cancer
Zhang, C., & Zhou, D. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1165908 · Cited by 110
“117 In the accelerated experiments, the animals were given AdHu5 expressing GP and NP of Ebola virus twice at doses of 2£10 12 vp with a 9week interval.”
MethodHamer, M. J., Houser, K. V., Hofstetter, A. R., Ortega-Villa, A. M., Lee, C., Preston, A., Augustine, B., Andrews, C., Yamshchikov, G. V., Hickman, S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02400-x · Cited by 69
Self-citationCircumventing Antivector Immunity: Potential Use of Nonhuman Adenoviral Vectors
Lopez-Gordo, E., Podgorski, I. I., Downes, N., & Alemany, R. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.228 · Cited by 65
Metadata
- Authors
- Sullivan, N. J., Geisbert, T. W., Geisbert, J. B., Xu, L., Yang, Z.-Y., Roederer, M., Koup, R. A., Jahrling, P. B., & Nabel, G. J.
- Venue
- Nature
- Published
- 2003-08
- Volume
- 424
- Issue
- 6949
- Pages
- 681-684
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2094139772
- Cited by
- 462
- References
- 34
- FWCI
- 26.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.